Cell therapy's poster child: Chimeric antigen receptor T cell therapy / 生物工程学报
Chinese Journal of Biotechnology
;
(12): 2339-2349, 2019.
Artículo
en Chino
| WPRIM
| ID: wpr-781634
ABSTRACT
Chimeric antigen receptor T (CAR-T) cell therapy, which adoptively transfers engineered T cells expressing synthetic receptors to target specific antigens, has achieved great clinical success in treating hematological malignancies. Though FDA has approved two CAR-T products, CAR-T therapy can cause some side effects, such as cytokine release syndrome (CRS), neurotoxicity and B cell aplasia. Meanwhile, lacking tumor specific antigen and the suppressive tumor environment limit the efficacy of CAR-T therapy in solid tumor. This review focuses on the structural components, clinical applications and synthetic biology approaches on CAR-T cell design, and summarizes the challenges and perspectives of CAR-T therapy as a revolutionary cancer immunotherapy.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Receptores de Antígenos de Linfocitos T
/
Linfocitos T
/
Inmunoterapia Adoptiva
/
Tratamiento Basado en Trasplante de Células y Tejidos
/
Receptores Quiméricos de Antígenos
/
Inmunoterapia
Límite:
Niño
/
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Biotechnology
Año:
2019
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS